Skip to main content

Market Overview

GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi


Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY).

  • One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress.
  • Sanofi's Bioverativ subsidiary's programs supplement GBT's existing pipeline and support the company's strategy to address sickle cell disease from multiple approaches.
  • Under the terms of the agreement, GBT will conduct all research, development, regulatory, and commercialization activities worldwide.
  • Sanofi will receive an upfront payment and is entitled to payments up to approximately $353 million in milestone payments and single-digit tiered royalties on worldwide net sales.
  • Price Action: GBT shares are up 0.2% at $46.1, and SNY shares are up 0.4% at $48.9 in premarket on the last check Tuesday.

Related Articles (SNY + GBT)

View Comments and Join the Discussion!

Posted-In: Sickle Cell DiseaseBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at